BioNTech’s €500 Million Cost-Cutting Drive Puts Cancer Ambition Ahead of Pandemic Legacy

The German biotech is tearing up the blueprint that made it a household name. BioNTech is severing its last operational ties to the COVID-19 pandemic, handing over the remaining vaccine production to partner Pfizer and shuttering multiple manufacturing sites. The goal is stark: transform into a pure-play oncology company by 2029, with annual savings of €500 million to fund the transition.

The restructuring is already cutting deep. Several hundred jobs are being eliminated as the company consolidates its footprint and retools its workforce for the specialised production of cancer therapies. The move marks a definitive break with the mRNA juggernaut that generated billions during the health crisis.

A First-Quarter Loss That Tells the Story

The financial cost of this pivot is laid bare in the first-quarter 2026 results. Revenue slumped to €118.1 million, down 31% from €182.8 million a year earlier, as seasonal COVID vaccine demand evaporated. Analysts had expected roughly 30% more revenue, underscoring the structural challenge.

The net loss ballooned to €531.9 million, driven by research and development spending that topped half a billion euros. R&D outlays hit €557.0 million, up from €525.6 million in the prior-year period, with the bulk flowing into immuno-oncology programmes and antibody-drug conjugates. The integration of recent acquisitions — BioNTech China and CureVac — added further pressure to the bottom line.

Should investors sell immediately? Or is it worth buying BioNTech?

Management is bracing for a full-year revenue range of €2.0 billion to €2.3 billion, down from €2.9 billion in 2025, as COVID vaccine sales continue to slide in both Europe and the US. In Europe, multi-year contracts are expiring; in the US, the market remains fiercely competitive.

A Clinical Setback and a Share Buyback

The timing could hardly be worse. Pfizer and BioNTech were forced to halt a large US study of their updated COVID vaccine in healthy adults aged 50 to 64 — a demographic that still lacks full FDA approval for any COVID shot. The reason: insufficient enrolment to generate usable data. The companies insisted safety was not a factor, but the halt comes just as the FDA’s vaccine advisory committee meets in May, hoping for fresh data ahead of the autumn season.

To keep investors onside during the drought, BioNTech unveiled a billion-euro share buyback programme, funded from its hefty cash pile of roughly €16.8 billion in cash and securities. The market has so far shrugged. The stock trades at €78.65, down nearly 11% on the week and well below its 50-day moving average. The shares are now about 22% below their 52-week high.

Adding to the unease, Chief Operating Officer Sierk Poetting sold 50,000 shares in late April through a pre-arranged trading plan, trimming his stake by more than 11%.

BioNTech at a turning point? This analysis reveals what investors need to know now.

Pipeline Data as the Next Catalyst

Despite the rocky start to 2026, the board is sticking to its full-year revenue forecast and calling this the decisive phase of execution. Six major data readouts from late-stage clinical trials are due by year-end, including results from the ROSETTA-Lung02 study. Among the most anticipated are interim data from the pivotal Phase III trial of Gotistobart, a CTLA-4 antibody partnered with OncoC4, which showed a clinically meaningful survival benefit in squamous lung cancer at the European Lung Cancer Congress in March.

The company is betting that positive data from these programmes — spanning immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies — will validate its high-stakes bet. If the numbers deliver, the next milestone comes into view: the first commercial oncology product launch in 2027. Until then, BioNTech is burning cash, closing factories, and hoping its pipeline can fill the void left by the pandemic.

Ad

BioNTech Stock: New Analysis - 8 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH’S | boerse | 69291004 |